IFN-γ联合拉米夫定治疗慢性乙型肝炎临床观察  

Therapeutic effects of recombinant human interferon plus lamivudine on chronic hepatitis B

作　　者：符孔舟[1] 杨海萍[1] 

机构地区：[1]河南科技大学第一附属医院,洛阳471003

出　　处：《传染病信息》2004年第2期83-83,共1页Infectious Disease Information

摘　　要：目的观察IFN-γ(上生雷泰)联合拉米夫定治疗慢性乙型肝炎的疗效。方法 300例患者随机分为3组,每组100例,分别应用上生雷泰+拉米夫定,α-干扰素(赛若金)+拉米夫定,胸腺肽+拉米夫定,治疗18个月后检测ALT复常率、HBeAg阴转率、抗HBe阳转率、HBV DNA(PCR法)阴转率。结果上生雷泰+拉米夫定组ALT复常率75％,HBeAg刚转率38％,抗HBe阳转率30％,HBV DNA阴转率73％;赛若金+拉米夫定组ALT常率65％,HBeAg阴转率20％,抗HBe阳转率7％,HBV DNA阴转率52％;胸腺肽+拉米夫定组ALT复常率65％,HBeAg阴转率20％,抗HBe阳转率7％,HBV DNA阴转率52％;胸腺肽+拉米夫定组ALT复常率35％,HBeAg阴转率10％,抗HBe阳转率7％,HBV DNA阴转率25％。结论上生雷泰+拉米夫定组疗效优于赛若金+拉米夫定组及胸腺肽+拉米夫定组。经统计学处理,3组疗效有明显的差异。Objective To observe the efficacy of recom- binant human interferon ( IFN-γ) plus lamividine in treatment of chronic hepatitis B. Methods A total of 300 patients with chro- nic hepatitis B were equally divided into 3 groups. IFN - γ plus lamivudine, sinugen plus lamivudine and thymopnlypetides plus lamivudine were given to the patients in groups A, B and C, re- spectively, for 1.5 years. Then the ALT recovery rate, HBeAg negative conversion rate, anti - HBe positive conversion rate and HBV DNA negative conversion rate were determined in all the 3 groups. Results The ALT recovery rate was 7.5%, 65% and 35%, HBeAg negative rate 38%, 0% and 20%, anti - HBe positive rate 30%, 7% and 7% ant HBV DNA negative rate 73% , 52% and 25% in groups A, B and C, respectively. Con- clusions The therapeutic efficacy of IFN -γ plus lamivudine is superior to that of sinogen plus lamivudie and thymopolypetides plus lamivudine.

关 键 词：IFN-Γ 联合 拉米夫定 治疗 慢性乙型肝炎 临床观察 

分 类 号：R512.62[医药卫生—内科学]